Stockreport

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results [Yahoo! Finance]

MaxCyte, Inc.  (MXCT) 
PDF ROCKVILLE, MD, March 4, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance [Read more]